IP Library Granted Patent US 7,226,771
Granted Patent B2
US 7,226,771 · App. 10/796,907 · Granted Jun 5, 2007

Phospholipases, nucleic acids encoding them and methods for making and using them

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,226,771
App. No.
10/796,907
Granted
Jun 5, 2007
Kind
B2
Abstract

The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.

Claims (41)

1. An isolated, synthetic or recombinant phospholipase (a) encoded by a phospholipase-encoding nucleic acid having at least 90% sequence identity to SEQ ID NO:1; (b) having a sequence comprising enzymatically active fragments of (a); (c) having the sequence of (a) or (b) and lacking an endogenous signal sequence; (d) having the sequence of (a), (b) or (c) and further comprising a heterologous signal sequence; or (e) having the sequence of (a), (b), (c) or (d) and further comprising a heterologous signal sequence,

and optionally the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection.

2. An isolated, synthetic or recombinant polypeptide having a phospholipase activity and (i) having at least 90% sequence identity to SEQ ID NO:2 wherein optionally the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection, or, (ii) encoded by a nucleic acid having at least 90% sequence identity to the sequence of SEQ ID NO:1, and optionally the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection, or

(iii) having the sequence of (i) or (ii) and lacking an endogenous signal sequence; or

(iv) having the sequence of (i), (ii) or (iii) and further comprising a heterologous signal sequence; or

(v) having the sequence of (i), (ii), (iii) or (iv) and further comprising a heterologous signal sequence.

3. The isolated, synthetic or recombinant polypeptide of claim 2 , wherein the polypeptide has a phospholipase C (PLC) activity.

4. The isolated, synthetic or recombinant polypeptide of claim 3 , wherein the phospholipase activity comprises catalyzing hydrolysis of a glycerolphosphate ester linkage; comprises catalyzing hydrolysis of an ester linkage in a phospholipid in a vegetable oil; comprises a phospholipase C (PLC) activity; comprises a phospholipase A (PLA) activity; comprises a phospholipase A1 or phospholipase A2 activity; comprises a phospholipase D (PLD) activity; comprises a phospholipase D1 or a phospholipase D2 activity; comprises hydrolysis of a glycoprotein; comprises a patatin enzymatic activity; or, comprises a lipid acyl hydrolase (LAH) activity.

5. An isolated, synthetic or recombinant polypeptide comprising the polypeptide of claim 2 and lacking a signal sequence.

6. An isolated, synthetic or recombinant polypeptide comprising the polypeptide of claim 2 and having a heterologous signal sequence.

7. A protein preparation comprising the polypeptide of claim 2 , wherein the protein preparation comprises a liquid, a solid or a gel.

8. A heterodimer or homodimer comprising the polypeptide of claim 2 and a second domain.

9. An immobilized polypeptide, wherein the polypeptide comprises the sequence of claim 2 .

10. A chimeric polypeptide comprising at least a first domain comprising signal peptide (SP) and a polypentide having the sequence of claim 2 , and at least a second domain comprising a heterologous polypeptide or peptide, wherein the heterologous polypeptide or peptide is not naturally associated with the signal peptide (SP).

11. The isolated, synthetic or recombinant polypeptide of claim 1 , wherein the sequence identity is at least 91%.

12. The isolated, synthetic or recombinant polypeptide of claim 11 , wherein the sequence identity is at least 92%.

13. The isolated, synthetic or recombinant polypeptide of claim 12 , wherein the sequence identity is at least 93%.

14. The isolated, synthetic or recombinant polypeptide of claim 13 , wherein the sequence identity is at least 94%.

15. The isolated, synthetic or recombinant polypeptide of claim 14 , wherein the sequence identity is at least 95%.

16. The isolated, synthetic or recombinant polypeptide of claim 15 , wherein the sequence identity is at least 96%.

17. The isolated, synthetic or recombinant polypeptide of claim 16 , wherein the sequence identity is at least 97%.

18. The isolated, synthetic or recombinant polypeptide of claim 17 , wherein the sequence identity is at least 98%.

19. The isolated, synthetic or recombinant polypeptide of claim 18 , wherein the sequence identity is at least 99%.

20. The isolated, synthetic or recombinant polypeptide of claim 19 , wherein the polypeptide has the sequence of SEQ ID NO:2, or enzymatically active fragments thereof.

21. The isolated, synthetic or recombinant polypeptide of claim 2 , wherein the sequence identity to SEQ ID NO:2 or to SEQ ID NO:1 is at least 91%.

22. The isolated, synthetic or recombinant polypeptide of claim 21 , wherein the sequence identity to SEQ ID NO:2 or to SEQ ID NO:1 is at least 92%.

23. The isolated, synthetic or recombinant polypeptide of claim 22 , wherein the sequence identity to SEQ ID NO:2 or to SEQ ID NO:1 is at least 93%.

24. The isolated, synthetic or recombinant polypeptide of claim 23 , wherein the sequence identity to SEQ ID NO:2 or to SEQ ID NO:1 is at least 94%.

25. The isolated, synthetic or recombinant polypeptide of claim 24 , wherein the sequence identity to SEQ ID NO:2 or to SEQ ID NO:1 is at least 95%.

26. The isolated, synthetic or recombinant polypeptide of claim 25 , wherein the sequence identity to SEQ ID NO:2 or to SEQ ID NO:1 is at least 96%.

27. The isolated, synthetic or recombinant polypeptide of claim 26 , wherein the sequence identity to SEQ ID NO:2 or to SEQ ID NO:1 is at least 97%.

28. The isolated, synthetic or recombinant polypeptide of claim 27 , wherein the sequence identity to SEQ ID NO:2 or to SEQ ID NO:1 is at least 98%.

29. The isolated, synthetic or recombinant polypeptide of claim 28 , wherein the sequence identity to SEQ ID NO:2 or to SEQ ID NO:1 is at least 99%.

30. The isolated, synthetic or recombinant polypeptide of claim 29 , wherein the polypeptide has the sequence of SEQ ID NO:2.

31. The isolated, synthetic or recombinant polypeptide of claim 30 , wherein the polypeptide has the sequence of SEQ ID NO:2, or enzymatically active fragments thereof.

32. An isolated, synthetic or recombinant polypeptide having a phospholipase activity and (a) comprising a sequence having at least 90% sequence identity to at least 100 contiguous amino acid residues of SEQ ID NO:2; (b) having the sequence of (a) and lacking an endogenous signal sequence; (c) having the sequence of (a) or (b) and further comprising a heterologous signal sequence; or (d) having the sequence of (a), (b) or (c) and further comprising a heterologous signal sequence.

33. The isolated, synthetic or recombinant polypeptide of claim 32 , wherein the sequence has at least 90% sequence identity to at least 150 contiguous amino acid residues of SEQ ID NO:2.

34. The isolated, synthetic or recombinant polypeptide of claim 33 , wherein the sequence has at least 90% sequence identity to at least 175 contiguous amino acid residues of SEQ ID NO:2.

35. The isolated, synthetic or recombinant polypeptide of claim 34 , wherein the sequence has at least 90% sequence identity to at least 200 contiguous amino acid residues of SEQ ID NO:2.

36. The isolated, synthetic or recombinant polypeptide of claim 35 , wherein the sequence has at least 90% sequence identity to at least 250 contiguous amino acid residues of SEQ ID NO:2.

37. The isolated, synthetic or recombinant polypeptide of claim 36 , wherein the sequence has at least 90% sequence identity to at least 275 contiguous amino acid residues of SEQ ID NO:2.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2013
From: DSM FOOD SPECIALTIES B.V.
To: DSM IP ASSETS B.V.
Reel/Frame 029708/0517 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE, ASSIGNEE NAME AND ADDRESS ON NOTICE OF RECORDATION PREVIOUSLY RECORDED ON REEL 028097 FRAME 0054. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT NATURE OF CONVENYANCE TO "ASSIGNMENT", AND ASSIGNEE'S NAME TO DSM FOOD SPECIALTIES B.V. Recorded Dec 17, 2012
From: VERENIUM CORPORATION
To: DSM FOOD SPECIALITES B.V.
Reel/Frame 029477/0729 →
RELEASE OF SECURITY INTEREST Recorded Jun 1, 2012
From: COMERICA BANK
To: VERENIUM CORPORATION
Reel/Frame 028300/0200 →
CHANGE OF NAME Recorded Apr 24, 2012
From: VERENIUM CORPORATION
To: DSM IP ASSETS B.V.
Reel/Frame 028097/0054 →
SECURITY AGREEMENT Recorded Oct 21, 2011
From: VERENIUM CORPORATION, A DELAWARE CORPORATION
To: COMERICA BANK, A TEXAS BANKING ASSOCIATION
Reel/Frame 027099/0408 →